Florian Huemer

4.3k total citations
46 papers, 502 citations indexed

About

Florian Huemer is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Florian Huemer has authored 46 papers receiving a total of 502 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 18 papers in Pulmonary and Respiratory Medicine and 9 papers in Pathology and Forensic Medicine. Recurrent topics in Florian Huemer's work include Colorectal Cancer Treatments and Studies (10 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Lung Cancer Research Studies (8 papers). Florian Huemer is often cited by papers focused on Colorectal Cancer Treatments and Studies (10 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Lung Cancer Research Studies (8 papers). Florian Huemer collaborates with scholars based in Austria, United States and Poland. Florian Huemer's co-authors include Richard Greil, Lukas Weiß, Gabriel Rinnerthaler, Hubert Hackl, Thomas Melchardt, Simon Peter Gampenrieder, Georg Hutarew, Theresa Westphal, Nadja Zaborsky and Alexander Egle and has published in prestigious journals such as Cancer Research, International Journal of Molecular Sciences and Annals of Oncology.

In The Last Decade

Florian Huemer

44 papers receiving 496 citations

Peers

Countries citing papers authored by Florian Huemer

Since Specialization

Citations

This map shows the geographic impact of Florian Huemer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Florian Huemer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Florian Huemer more than expected).

Fields of papers citing papers by Florian Huemer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Florian Huemer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Florian Huemer. The network helps show where Florian Huemer may publish in the future.

Co-authorship network of co-authors of Florian Huemer

This figure shows the co-authorship network connecting the top 25 collaborators of Florian Huemer. A scholar is included among the top collaborators of Florian Huemer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Florian Huemer. Florian Huemer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Multidimensional differences of right- and left-sided colorectal cancer and their impact on targeted therapies 2025 ·npj Precision Oncology ·(unknown), (unknown), (unknown), Michael Günther, Arno Amann, (unknown), (unknown), (unknown), Steffen Ormanns, (unknown), Romana R. Gerner, Florian Kocher, (unknown), Dominik Wolf‎, Jakob M. Riedl, Florian Huemer, Andreas Seeber	5
2	Image-based consensus molecular subtyping in rectal cancer biopsies and response to neoadjuvant chemoradiotherapy 2024 ·npj Precision Oncology ·Maxime W. Lafarge, Enric Domingo, Korsuk Sirinukunwattana, (unknown), Leslie Samuel, Graeme I. Murray, Susan D. Richman, Andrew Blake, David Sebag‐Montefiore, Simon Gollins, E. Klieser, Daniel Neureiter, Florian Huemer, Richard Greil, Philip D. Dunne, Philip Quirke, Lukas Weiß, Jens Rittscher, Tim Maughan, Viktor H. Koelzer	9
3	Unraveling Resistance to Immunotherapy in MSI-High Colorectal Cancer 2023 ·Cancers ·(unknown), Florian Huemer, M. Steiner, (unknown), Richard Greil, Lukas Weiß	27
4	Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab‐paclitaxel as first‐line chemotherapy for advanced pancreatic adenocarcinoma: A single‐center retrospective analysis 2023 ·Cancer Medicine ·Konstantin Schlick, (unknown), (unknown), Florian Huemer, Richard Greil, Lukas Weiß	3
5	Management of metastatic colorectal cancer in patients ≥70 years - a single center experience 2023 ·Frontiers in Oncology ·Florian Huemer, (unknown), Gabriel Rinnerthaler, Konstantin Schlick, (unknown), Klaus Emmanuel, Daniel Neureiter, E. Klieser, (unknown), Falk Roeder, Richard Greil, Lukas Weiß	0
6	Multimodal Treatment of Malignant Pleural Mesothelioma: Real-World Experience with 112 Patients 2022 ·Cancers ·(unknown), (unknown), Maximilian J. Hochmair, (unknown), Ulrike Setinek, Florian Huemer, (unknown), (unknown), (unknown), (unknown), Michael Weber, Gunther Leobacher, Arschang Valipour, Michael Mueller, Stefan Watzka	1
7	Body composition dynamics and impact on clinical outcome in gastric and gastro-esophageal junction cancer patients undergoing perioperative chemotherapy with the FLOT protocol 2022 ·Journal of Cancer Research and Clinical Oncology ·Florian Huemer, Stefan Hecht, (unknown), (unknown), Gabriel Rinnerthaler, Konstantin Schlick, (unknown), Thomas Melchardt, A Wimmer, (unknown), Oliver Koch, Daniel Neureiter, E. Klieser, (unknown), Mohsen Beheshti, Richard Greil, Lukas Weiß	7
8	Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrence 2021 ·ESMO Open ·Teresa Magnes, (unknown), Aaron R. Thorner, Daniel Neureiter, E. Klieser, Gabriel Rinnerthaler, (unknown), Florian Huemer, Nadja Zaborsky, M. Steiner, Stefan Weis, Richard Greil, Alexander Egle, Thomas Melchardt	10
9	Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone 2021 ·Wiener klinische Wochenschrift ·Teresa Magnes, (unknown), Thomas Melchardt, Lukas Weiß, Gabriel Rinnerthaler, Florian Huemer, Michael Kopp, Simon Peter Gampenrieder, (unknown), Thorsten Füreder, (unknown), Johannes Andel, Alexander Egle, Richard Greil	5
10	Evaluation of circulating cell-free KRAS mutational status as a molecular monitoring tool in patients with pancreatic cancer 2021 ·Pancreatology ·Konstantin Schlick, (unknown), Florian Huemer, (unknown), Nadja Zaborsky, Clemens Hufnagl, Daniel Neureiter, (unknown), (unknown), (unknown), (unknown), (unknown), Lukas Weiß, Thomas Melchardt, Richard Greil, Alexander Egle	9
11	Sustained response to brigatinib in a patient with refractory metastatic pheochromocytoma harboring R1192P anaplastic lymphoma kinase mutation: a case report from the Austrian Group Medical Tumor Therapy next-generation sequencing registry and discussion of the literature 2021 ·ESMO Open ·(unknown), Florian Huemer, Georg Hutarew, Stefan Hecht, (unknown), Dieter Kotzot, (unknown), Gabriel Rinnerthaler, Thomas Melchardt, (unknown), Richard Greil	2
12	Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal Cancer 2019 ·Clinical Colorectal Cancer ·Florian Huemer, (unknown), Stefan Hecht, Hubert Hackl, Thomas Melchardt, Gabriel Rinnerthaler, Richard Greil, Lukas Weiß	18
13	Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study 2019 ·Targeted Oncology ·David Lang, Florian Huemer, Gabriel Rinnerthaler, Andreas Horner, (unknown), (unknown), Kaveh Akbari, (unknown), Georg Hutarew, Bernhard Kaiser, Richard Greil, Bernd Lamprecht	12
14	Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie) 2018 ·BMC Cancer ·Florian Huemer, Josef Thaler, (unknown), Hubert Hackl, Lisa Pleyer, Clemens Hufnagl, Lukas Weiß, Richard Greil	16
15	PL02.07 IMpower 133: Primary PFS, OS and Safety in a PH1/3 Study of 1L Atezolizumab + Carboplatin + Etoposide in Extensive-Stage SCLC 2018 ·Journal of Thoracic Oncology ·Stephen V. Liu, Aaron S. Mansfield, Aleksandra Szczęsna, Libor Havel, Maciej Krzakowski, Maximilian J. Hochmair, Florian Huemer, György Losonczy, Michele H. Johnson, Makoto Nishio, M. Reck, Tony Mok, S. Lam, (unknown), (unknown), Beiying Ding, Fairooz F. Kabbinavar, Wei Lin, A. Sandler, Leora Horn	5
16	Establishment and validation of a novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemia 2018 ·Wiener klinische Wochenschrift ·Florian Huemer, Lukas Weiß, (unknown), Daniel Neureiter, Alexander Egle, Klaus Geißler, Daniela Voskova, Armin Zebisch, Sonja Burgstaller, (unknown), Reinhard Stauder, Wolfgang R. Sperr, Alois Lang, Michael Pfeilstöcker, Sigrid Machherndl‐Spandl, (unknown), Richard Greil, Lisa Pleyer	1
17	Extensive Leptomeningeal Intracranial and Spinal Metastases in a Patient with a Supratentorial Glioblastoma Multiforme, IDH-Wildtype 2018 ·World Neurosurgery ·Christoph Schwartz, Alexander Romagna, (unknown), Lukas Weiß, Florian Huemer, Gerd Fastner, Waltraud Kleindienst, Serge Weis, Richard Greil, Peter Winkler	7
18	Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer 2016 ·The Pharmacogenomics Journal ·Simon Peter Gampenrieder, Clemens Hufnagl, (unknown), Florian Huemer, Hubert Hackl, Gabriel Rinnerthaler, (unknown), (unknown), (unknown), Cornelia Hauser‐Kronberger, Brigitte Mlineritsch, Richard Greil	6
19	Immune checkpoint blockade in ovarian cancer 2016 ·memo - Magazine of European Medical Oncology ·Lukas Weiß, Florian Huemer, Brigitte Mlineritsch, Richard Greil	14
20	Independent Prognostic Value of Serum Markers in Diffuse Large B-Cell Lymphoma in the Era of the NCCN-IPI 2015 ·Journal of the National Comprehensive Cancer Network ·Thomas Melchardt, Katharina Troppan, Lukas Weiß, Clemens Hufnagl, Daniel Neureiter, Wolfgang Tränkenschuh, Konstantin Schlick, Florian Huemer, Alexander Deutsch, Peter Neumeister, Richard Greil, Martin Pichler, Alexander Egle	25

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact